Intuitive Surgical Sits 33% Below Its Two-Year High – Why a 95/100 Quality Score Still Only Earns a Hold

Intuitive Surgical, maker of the da Vinci robotic surgery system, closed at $401.24, about 33% below its two-year high of $595.55. The business behind the share price is still growing quickly – revenue up 18.5% over the trailing twelve months to $11.0 billion, with a 33.6% operating margin – and it earns a near-perfect Quality score of 95/100. This Intuitive Surgical stock analysis, based on Yahoo Finance data as of October 2, 2026, explains why the scoring model nonetheless rates the stock a Hold: at 46.12 times earnings, the valuation leaves little margin for error.

What Is Happening With the Stock Price

At $401.24, the shares sit in the lower end of their two-year range of $337.50 to $595.55, about 19% above the low. According to published reports, the decline has been driven by slower U.S. procedure growth and new competition, with rival robotic systems from Medtronic (Hugo) and Johnson & Johnson (Ottava) gaining regulatory clearances in soft-tissue surgery. The business itself has kept growing: in the second quarter, Intuitive reported revenue of $2.89 billion, up 19%, worldwide procedures up about 16% and 468 da Vinci systems placed. U.S. da Vinci procedures grew a slower 12%, however, and management guided to full-year procedure growth of roughly 13.5% to 15.5%.

Quality: Is This a Financially Sound Business?

Quality scores 95/100, and this Intuitive Surgical stock analysis finds little to criticize. Gross margin is 66.7%, operating margin 33.6% and net profit margin 28.4%, earned from an installed base the company put at 11,710 da Vinci systems at the end of June. Free cash flow was $2.6 billion over the trailing twelve months, about 83% of the roughly $3.1 billion of net income implied by the margin – solid conversion, if below one-for-one.

The balance sheet is very strong. The current ratio is 4.96 and the quick ratio 3.64; debt-to-equity is not reported in the data, and an enterprise value below the market capitalization implies more cash than debt. Intuitive reported $8.63 billion of cash and investments at June 30, 2026. Return on equity of 17.4% and return on assets of 10.5% are good rather than exceptional, partly because so much of the balance sheet is held in cash and investments.

Growth: Does This Company Have Real Upside?

Growth scores 64/100. Revenue rose 18.5% over the trailing twelve months, closely matching the 17.4% five-year CAGR, and earnings grew faster at 26.5%. Combining blended revenue growth with a 23.7% free-cash-flow margin gives a Rule of 40 reading of about 42, just above the benchmark. The score is held back by the model’s high bar for revenue momentum and by an EV/Revenue multiple of 12.56, which means a good deal of future growth is already priced in. The longer-term question is whether new competitors and slower U.S. procedure growth erode a pace the company has sustained for five years.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores 27/100, and this is where the signal is decided. A P/E of 46.12 equals an earnings yield of only about 2.2%, EV/EBITDA is 33.14, the free-cash-flow yield is 1.8% and price-to-book is 7.82. Even against 26.5% earnings growth, the P/E-to-growth ratio is about 1.7. The model does give credit for the shares trading in the lower end of their two-year range – with Quality this high, it treats the pullback as a potential contrarian setup rather than a value trap – but that cannot offset the rich multiples. The Recommendation Score of 62/100 clears the model’s Buy threshold of 60, yet a Buy also requires Opportunity of at least 30/100, so Intuitive Surgical lands at Hold.

Intuitive Surgical Stock Analysis: The Bottom Line

This Intuitive Surgical stock analysis ends with a model signal of Hold and a Recommendation Score of 62/100, combining Quality 95/100, Growth 64/100 and Opportunity 27/100. The bull case: a large and growing installed base, 18.5% revenue growth, 26.5% earnings growth, a 33.6% operating margin, a cash-rich balance sheet and a share price a third below its two-year high. The bear case: a P/E of 46.12 and a 1.8% free-cash-flow yield that already assume years of strong growth, rising competition from Medtronic and Johnson & Johnson, softer U.S. procedure growth, and tariffs that the company estimates will cost about 1.0% of revenue in gross margin this year. If growth slows further, the premium multiple could compress – the central risk at this valuation.

The Hold label reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity) – a data-driven signal for further research, not a personalized recommendation to transact. Medical device stocks can move sharply on procedure data, hospital capital budgets and regulatory decisions.